Tarina 24 Fe Kit
Product Images NDC 50102-224

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tarina 24 Fe (NDC 50102-224). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Afaxys Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Norethindroneethinyl Fig1)

This appears to be a list of studies comparing the effects of using combined oral contraceptives (COC) to not using them (never-use) on various health outcomes. The studies listed include the NICHD Women's Care Study, French E3N cohort Study, Shanghai Women's Health Study, The Nurses' Health Study, Oxford Family Planning Study, and Danish Sex Hormone Register Study. The table at the bottom shows effect estimates for the different studies, but without more context, it is difficult to interpret the numbers.*

FDA Label Image

Figure-2 (Norethindroneethinyl Fig2)

FDA Label Image

Figure (Norethindroneethinyl Fig3)

FDA Label Image

Figure4 (Norethindroneethinyl Fig4)

This text provides information on different birth control methods and their effectiveness in preventing pregnancy. It includes statistics on the number of pregnancies per 100 women in one year for various methods of birth control, including hormonal options like implants and pills, barrier methods like condoms and diaphragms, and non-hormonal methods like spermicide and withdrawal. The text also mentions natural family planning methods like avoiding sex during the most fertile days of the monthly cycle.*

FDA Label Image

Package Label-principal Display Panel (1 mg/20 mcg Pouch Label)

FDA Label Image

Package Label-principal Display Panel (1 mg/20 mcg Pouch Carton Label)

Tarinaf® 24 Fe is a pharmaceutical product that provides 24 days of active therapy. It consists of Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets. Each pouch contains detailed patient labeling, brief summary, patient package insert and day label stickers along with the blister. A 28-day regimen is recommended with one tablet including Combination Detaled Patient Labefing / Brief Summary. Proper storage conditions are mentioned for the product. Overall, Tarinaf® 24 Fe helps with female therapy.*

FDA Label Image

Norethindroneethinyl Fig7

Tarina® 24 Fo is an oral contraceptive product consisting of 24 days of active therapy. The product is manufactured by Afaxys Pharma for Aurobindo Pharma Limited in India. The product's NDC is 50102-224-23. It should be noted that Tarina® 24 Fo is not intended to protect against HIV infection or other sexually transmitted diseases. The text includes additional information that is difficult to understand.*

FDA Label Image

Structure-1 (Norethindroneethinyl Str1)

FDA Label Image

Structure-2 (Norethindroneethinyl Str2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.